Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Raechele Simpson

Nurse Practitioner, Family Anderson, SC Nurse Practitioner

NPI 1225400997 CMS profile 11059650

100 Healthy Way, Anderson, SC 29621

Open in the dashboard

General payments

$7,720

403 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Raechele Simpson of Anderson, SC is reported in the CMS Open Payments database as having received $7,720 across 403 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,637 65
2024 General $1,156 73
2023 General $967 50
2022 General $1,851 90
2021 General $2,109 125

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Raechele Simpson
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Raechele Simpson were reported at $1,637. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Raechele Simpson Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,109 $124 $35–$379 $132
2022 $1,851 $141 $44–$430 $149
2023 $967 $154 $49–$476 $160
2024 $1,156 $165 $51–$504 $164
2025 $1,637 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Forte Bio-Pharma LLC $1,785 73 payments
  2. Boston Scientific Corporation $1,697 93 payments
  3. Scilex Pharmaceuticals Inc. $1,272 64 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $444 25 payments
  5. AbbVie, Inc. $418 27 payments
  6. Teva Pharmaceuticals USA, Inc. $276 19 payments
  7. Biohaven Pharmaceuticals, Inc. $275 12 payments
  8. Collegium Pharmaceutical, Inc. $256 15 payments
  9. Amgen Inc. $252 10 payments
  10. Arbor Pharmaceuticals, Inc. $164 13 payments
  11. Other $881 52 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,720 400 payments
  2. Gift $0 3 payments
Products named General payments · program years 2021–2025
  1. PROLATE Pain $1,642 72 payments
  2. PROLATE Pain $1,642 72 payments
  3. PROLATE Pain $1,642 72 payments
  4. NALOCET $1,642 72 payments
  5. ZTLido $1,093 55 payments
  6. PROLATE Pain $1,088 50 payments
  7. TANLOR $554 22 payments
  8. WaveWriter Alpha Prime 16 $518 15 payments
  9. RELISTOR $419 24 payments
  10. General - Pain Management $418 18 payments
  11. Other $3,723 207 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

5,124

Median for Nurse Practitioner: 389

Drug cost

$217,259

Median for Nurse Practitioner: $21,885

Branded share of claims

5.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Relistor Methylnaltrexone Bromide Brand 14 $33,064
Belbuca Buprenorphine Hcl Brand 48 $31,838
Buprenorphine Generic 88 $27,037
Aimovig Autoinjector Erenumab-Aooe Brand 19 $19,988
Celecoxib Generic 728 $12,730
Lidocaine Generic 126 $10,313
Gabapentin Generic 695 $10,057
Movantik Naloxegol Oxalate Brand 21 $9,041
Ztlido Lidocaine Brand 22 $9,039
Butrans Buprenorphine Brand 19 $8,119

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZTLido
  • Scilex Pharmaceuticals Inc. $369
$369 22 —
PROLATE
  • Forte Bio-Pharma LLC $341
$341 — —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $99
$99 14 —
NALOCET
  • Forte Bio-Pharma LLC $85
$85 — —
UBRELVY
  • AbbVie, Inc. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

403 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record